A New 20% Concentration Immunoglobulin for Subcutaneous Administration (IGSC 20%)
نویسندگان
چکیده
منابع مشابه
Immune Globulin Subcutaneous (Human) 20%
Immune globulin subcutaneous 20% is a new high-concentration (200 g/L) solution of highly purified human IgG (≥98%) indicated in the EU and the US for antibody replacement therapy in patients with primary immunodeficiency with antibody deficiency, and in the EU for replacement therapy in humoral immunodeficiency secondary to myeloma or chronic lymphocytic leukaemia. Immune globulin subcutaneous...
متن کاملShift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®) has been developed and has replaced Vivaglobin® (SCIG 16%). An observational prospective multi-centric open-label study, with retrospective comparison was conducted ...
متن کاملO 20: The Role of Neuroinflammation in Epilepsy: A New Target for Treatment
Despite progress in pharmacological and surgical treatments of epilepsy, little is known about the processes that a healthy brain is rendered epileptic after seizure occurrence. Growing evidence supports the involvement of inflammatory processes, both the adaptive immunity and systemic inflammatory response, in induction of individual seizures as well as in the epileptogenesis. Clinical and exp...
متن کاملEfficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evaluated in a prospective trial in Europe in 49 patients with PIDD aged 2-67 years. Over a median of ...
متن کاملNew Frontiers in Subcutaneous Immunoglobulin Treatment
Subcutaneous immunoglobulin (SCIG) treatment provides stable serum immunoglobulin G (IgG) levels, is associated with fewer systemic adverse events than intravenous immunoglobulin (IVIG) treatment, and offers the convenience of home therapy. In clinical practice, IVIG is still used preferentially for initiation of treatment in newly diagnosed patients with primary immunodeficiency (PI) and for i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Allergy and Clinical Immunology
سال: 2019
ISSN: 0091-6749
DOI: 10.1016/j.jaci.2018.12.045